The Lung Adenocarcinoma drugs in development market research report provides comprehensive information on the therapeutics under development for Lung Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Lung Adenocarcinoma. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Lung Adenocarcinoma - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Lung Adenocarcinoma and features dormant and discontinued products.

GlobalData tracks 78 drugs in development for Lung Adenocarcinoma by 68 companies/universities/institutes. The top development phase for Lung Adenocarcinoma is phase ii with 24 drugs in that stage. The Lung Adenocarcinoma pipeline has 69 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Lung Adenocarcinoma pipeline products market are: Boehringer Ingelheim International, Jiangsu Hengrui Medicine and Johnson & Johnson.

The key targets in the Lung Adenocarcinoma pipeline products market include Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC, GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC, and Cells Expressing Mesothelin (CAK1 Antigen or Pre Pro Megakaryocyte Potentiating Factor or MSLN).

The key mechanisms of action in the Lung Adenocarcinoma pipeline product include Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC Inhibitor with five drugs in Phase III. The Lung Adenocarcinoma pipeline products include 12 routes of administration with the top ROA being Intravenous and eight key molecule types in the Lung Adenocarcinoma pipeline products market including Small Molecule, and Monoclonal Antibody.

Lung Adenocarcinoma overview

Lung adenocarcinoma is the most common type of non-small cell lung cancer (NSCLC), accounting for a significant portion of lung cancer cases. It typically arises in the outer regions of the lungs and tends to develop in the smaller airways, known as bronchioles. Adenocarcinoma is characterized by cancerous cells that form glandular structures resembling the normal cells found lining the lungs. It tends to grow more slowly compared to other types of lung cancer, and it’s often diagnosed in non-smokers or former light smokers. However, it can occur in individuals with a history of smoking as well. The symptoms of lung adenocarcinoma can vary but commonly include persistent coughing, chest pain, shortness of breath, coughing up blood, fatigue, unexplained weight loss, and recurrent respiratory infections.

For a complete picture of Lung Adenocarcinoma’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.